Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting ...
Omjjara (momelotinib) – which has been predicted by GSK to have blockbuster sales potential – was approved as Ojjaara by the US FDA in September after a three-month delay. It can be used in ...
Hosted on MSN3mon
GSK slips as vaccine outlook is slashedSpecialty medicines performed particularly well, exceeding expectations by 6%, driven by strong sales of Dovato and a launch of Ojjaara, said analysts at Jefferies in a note. General medicines saw ...
Consistent improvement in patient-reported outcomes with six... Nov 12, 2024, 13:00 ET Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to ...
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback